PDCD1 and cancer: Despite effective restorement of anti-cancer immunity by nivolumab and ipilimumab, the blockade of PD-1 and CTLA-4, both of which are negative regulators of adaptive and innate immunity, sometimes causes excessive immune reactions in a broad range of organs, called immune-related adverse events (irAEs) [3, 4].